Join
Live feed
·
PRReleasevia Quantisnow
Adagene Inc. logo

Adagene Announces NMPA Clearance of Investigational New Drug Application for ADG138, a Novel HER2xCD3 Double-Masked Bispecific T-Cell Engager

ByQuantisnow·Wall Street's wire, on your screen.
ADAG· Adagene Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ADAG (Adagene Inc.) and more on Quantisnow.